IGSF5

IGSF5 (JAM4) is an immunoglobulin-superfamily cell adhesion molecule that organizes epithelial junctions and the glomerular slit diaphragm through its two extracellular Ig-loops and a C-terminal PDZ-binding motif (PMID:12773569, PMID:16155592). It mediates calcium-independent homophilic adhesion and recruits the junctional scaffolds MAGI-1, ZO-1, and occludin to sites of cell contact, with MAGI-1 binding through the JAM4 carboxyl terminus and reinforcing adhesion and paracellular barrier sealing (PMID:12773569). The two Ig-loops are functionally divided: the first Ig-loop directs tight-junction localization and supports cis interactions, while both loops are required for trans homophilic adhesion, and JAM4 in turn dictates the subcellular distribution of MAGI-1 (PMID:12940823). In the kidney, JAM4 forms a tripartite complex with MAGI-1 and nephrin at the glomerular slit diaphragm, a localization that is disrupted in proteinuric injury where JAM4 redistributes apically and loses MAGI-1 colocalization (PMID:16155592, PMID:16118391). Beyond static adhesion, JAM4 signals to promote epithelial remodeling: it activates Rac GTPase to augment HGF-induced branching and scattering (PMID:15330858), and its surface levels are controlled by an LNX1–Numb scaffold that drives JAM4 endocytosis, contributing to TGF-β-induced receptor redistribution (PMID:16832352). Knockout mice lack overt histological defects in tissues where JAM4 is expressed, indicating functional redundancy with other adhesion molecules (PMID:16982697).

1. 2003 High

   Establishing that JAM4 is an adhesion molecule that nucleates a junctional scaffold answered whether it does more than mediate contact — it physically organizes the tight-junction protein network.

   Evidence In vitro binding assays, COS-7 coexpression, L-cell adhesion assays, and CHO monolayer permeability assays

   PMID:12773569

   Open questions at the time

   • Does not define the structural basis of MAGI-1 binding
   • Physiological tissue context of the adhesion not addressed in this study
2. 2003 Medium

   Domain dissection answered which parts of JAM4 carry out localization versus adhesion, separating tight-junction targeting and cis interactions (first Ig-loop) from trans adhesion (both loops).

   Evidence Deletion/domain mutant analysis with immunofluorescence and adhesion assays in MDCK cells

   PMID:12940823

   Open questions at the time

   • No structural model of the Ig-loops
   • Single-lab domain mapping without orthogonal validation
3. 2004 Medium

   Linking JAM4 to Rac activation answered whether it has a signaling role beyond adhesion, showing it augments HGF-driven epithelial branching and scattering.

   Evidence JAM4-overexpressing MDCK cells with HGF, GST-CRIB pulldown for active Rac, and dominant-negative Rac in COS-7 morphology assays

   PMID:15330858

   Open questions at the time

   • Mechanism coupling JAM4 to Rac GEFs unidentified
   • Relevance to endogenous JAM4 levels not established
4. 2005 High

   Placing JAM4 in a nephrin–MAGI-1 complex answered where it acts in vivo, localizing it to the glomerular slit diaphragm.

   Evidence Yeast two-hybrid, in vitro tripartite complex reconstitution, and immunoelectron microscopy

   PMID:16155592

   Open questions at the time

   • Functional consequence of the tripartite complex for filtration not tested
   • Stoichiometry and direct vs bridged interactions unresolved
5. 2005 Medium

   Examining injured podocytes answered whether JAM4 localization is dynamic in disease, revealing apical redistribution and loss of MAGI-1 colocalization in proteinuria.

   Evidence Immunoelectron microscopy and detergent-extraction fractionation in rat PAN nephropathy

   PMID:16118391

   Open questions at the time

   • Causal role of JAM4 redistribution in foot-process effacement unknown
   • Correlative disease-model observation
6. 2006 High

   Identifying the LNX1–Numb scaffold answered how JAM4 surface levels are controlled, defining an endocytic regulatory mechanism tied to TGF-β signaling.

   Evidence Yeast two-hybrid, co-IP from kidney lysates, in vitro tripartite binding, RNAi and dominant-negative endocytosis assays

   PMID:16832352

   Open questions at the time

   • Trigger linking TGF-β to LNX1-Numb recruitment unresolved
   • In vivo consequence of JAM4 endocytosis not tested
7. 2006 Medium

   Knockout mice answered whether JAM4 is individually required in its expressing tissues, showing no overt defect and implying redundancy.

   Evidence Signal sequence trap cloning, immunolocalization, and phenotypic analysis of JAM4-knockout mice (histology, flow cytometry)

   PMID:16982697

   Open questions at the time

   • Redundant adhesion molecules not identified
   • Subtle functional or stress-dependent phenotypes not probed
8. 2021 Medium

   Quantitative binding measurements answered whether JAM4 prefers homotypic or heterotypic partners, showing heterotypic JAM-family interactions can dominate.

   Evidence Surface plasmon resonance of recombinant MBP-fused extracellular domains

   PMID:33801758

   Open questions at the time

   • Cellular relevance of heterotypic JAM4 interactions untested
   • Specific JAM4 heterotypic partner affinities not detailed in context

• Whether JAM4 adhesion, Rac signaling, and slit-diaphragm assembly are integrated into a single regulatable pathway, and what physiological process specifically requires JAM4, remains open.
• No integrated in vivo loss-of-function phenotype defined
• Redundant partners and disease relevance unestablished